Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Assets (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Current Assets readings, the most recent being $2.5 billion for Q4 2025.

  • On a quarterly basis, Current Assets rose 46.27% to $2.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 billion, a 46.27% increase, with the full-year FY2025 number at $2.5 billion, up 46.27% from a year prior.
  • Current Assets hit $2.5 billion in Q4 2025 for Neurocrine Biosciences, up from $2.2 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $2.5 billion in Q4 2025 to a low of $972.8 million in Q4 2021.
  • Median Current Assets over the past 5 years was $1.6 billion (2023), compared with a mean of $1.5 billion.
  • Biggest five-year swings in Current Assets: fell 13.07% in 2021 and later soared 49.41% in 2022.
  • Neurocrine Biosciences' Current Assets stood at $972.8 million in 2021, then soared by 49.41% to $1.5 billion in 2022, then rose by 10.56% to $1.6 billion in 2023, then grew by 7.32% to $1.7 billion in 2024, then skyrocketed by 46.27% to $2.5 billion in 2025.
  • The last three reported values for Current Assets were $2.5 billion (Q4 2025), $2.2 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.